AbbVie’s atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA,

The NDA approval was supported by data from a pivotal Phase III ADVANCE multi-center clinical trial in patients who experienced four to 14 migraine …, The NDA approval was supported by data from a pivotal Phase III ADVANCE multi-center clinical trial in patients who experienced four to 14 migraine …, Read More

Scroll to Top